H. Lundbeck A/S

🇩🇰Denmark

Country: 🇩🇰Denmark

Ownership: Public, Subsidiary

Established: 2000-01-01

Employees: 5.6K

Market Cap: -

Website: http://www.lundbeck.com

Clinical Trials

Sertindole in Asian Patients With Schizophrenia

Phase 3

Completed

Conditions: Schizophrenia

Interventions: Drug: Olanzapine
Drug: Sertindole

First Posted Date: 2009-03-18

Last Posted Date: 2013-09-20

Lead Sponsor: H. Lundbeck A/S

Target Recruit Count: 394

Registration Number: NCT00864045

Locations: 🇨🇳
CN001, Beijing, China

A Clinical Study Evaluating the Effects of Memantine on Brain Atrophy in Patients With Alzheimer's Disease

Phase 4

Completed

Conditions: Alzheimer's Disease

Interventions: Drug: Memantine
Drug: Placebo

First Posted Date: 2009-03-17

Last Posted Date: 2012-09-03

Lead Sponsor: H. Lundbeck A/S

Target Recruit Count: 277

Registration Number: NCT00862940

Bifeprunox Extension to Extension Study in Patients With Schizophrenia

Phase 3

Terminated

Conditions: Schizophrenia

Interventions: Drug: Bifeprunox

First Posted Date: 2009-03-13

Last Posted Date: 2013-09-16

Lead Sponsor: H. Lundbeck A/S

Target Recruit Count: 11

Registration Number: NCT00861497

Locations: 🇮🇹
IT001, Brescia, Italy

Efficacy and Safety of Memantine in Moderate to Severe Alzheimer's Disease

Phase 3

Terminated

Conditions: Alzheimer's Disease

Interventions: Drug: Memantine
Drug: Placebo

First Posted Date: 2009-03-06

Last Posted Date: 2013-12-05

Lead Sponsor: H. Lundbeck A/S

Target Recruit Count: 369

Registration Number: NCT00857649

Locations: 🇨🇦
CA019, Edmonton, Alberta, Canada
🇨🇦
CA005, Beauport, Quebec, Canada
🇨🇦
CA009, Toronto, Ontario, Canada

and more 20 locations

Safety and Tolerability of Memantine in Moderate to Severe Alzheimer's Disease

Phase 3

Terminated

Conditions: Alzheimer's Disease

Interventions: Drug: Memantine

First Posted Date: 2009-03-06

Last Posted Date: 2012-08-29

Lead Sponsor: H. Lundbeck A/S

Target Recruit Count: 297

Registration Number: NCT00857233

Locations: 🇨🇦
CA022, St. John, New Brunswick, Canada
🇨🇦
CA043, Kelowna, British Columbia, Canada
🇨🇦
CA009, Toronto, Ontario, Canada

and more 30 locations

Safety Study of Sertindole Versus Risperidone Under Normal Conditions of Use

Phase 3

Completed

Conditions: Schizophrenia

Interventions: Drug: Sertindole
Drug: Risperidone

First Posted Date: 2009-03-06

Last Posted Date: 2011-08-19

Lead Sponsor: H. Lundbeck A/S

Target Recruit Count: 9809

Registration Number: NCT00856583

Efficacy and Safety Study of Desmoteplase to Treat Acute Ischemic Stroke (DIAS-4)

Phase 3

Terminated

Conditions: Stroke

Interventions: Drug: Placebo
Drug: Desmoteplase

First Posted Date: 2009-03-06

Last Posted Date: 2017-03-16

Lead Sponsor: H. Lundbeck A/S

Target Recruit Count: 270

Registration Number: NCT00856661

Locations: 🇺🇸
US077, Lebanon, New Hampshire, United States
🇺🇸
US064, Shreveport, Louisiana, United States
🇺🇸
US063, Fairfield, Connecticut, United States

and more 149 locations

Memantine Versus Placebo in Parkinson's Disease Dementia or Dementia With Lewy Bodies

Phase 4

Completed

Conditions: Parkinson's Disease Dementia
Dementia With Lewy Bodies

Interventions: Drug: Placebo
Drug: Memantine

First Posted Date: 2009-03-04

Last Posted Date: 2013-09-20

Lead Sponsor: H. Lundbeck A/S

Target Recruit Count: 199

Registration Number: NCT00855686

Locations: 🇩🇪
DE001, Munich, Germany

Randomised Placebo-controlled Venlafaxine-referenced Study of Efficacy and Safety of 5 and 10 mg of Vortioxetine (Lu AA21004) in Acute Treatment of Major Depressive Disorder in Adults

Phase 2

Completed

Conditions: Major Depressive Disorder

Interventions: Drug: Placebo
Drug: Vortioxetine (Lu AA21004)
Drug: Venlafaxine XL

First Posted Date: 2009-02-09

Last Posted Date: 2014-05-13

Lead Sponsor: H. Lundbeck A/S

Target Recruit Count: 426

Registration Number: NCT00839423

Efficacy of Nalmefene in Patients With Alcohol Dependence

Phase 3

Completed

Conditions: Alcohol Dependence

Interventions: Drug: Placebo
Drug: Nalmefene

First Posted Date: 2008-12-22

Last Posted Date: 2013-07-22

Lead Sponsor: H. Lundbeck A/S

Target Recruit Count: 678

Registration Number: NCT00812461

Locations: 🇫🇷
FR009, Clichy Cedex 92, France
🇪🇸
ES004, Barcelona, Spain
🇪🇸
ES002, Oviedo, Spain

and more 54 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy